Reportlinker Adds Inflammatory Bowel Disease: what the future holds

Tuesday, May 4, 2010 General News J E 4

NEW YORK, May 4 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Inflammatory Bowel Disease: what the future holds


- Unique sales forecasts by product to 2010

- Critical assessment and estimates, where appropriate, for 19 new compounds

- Detailed evaluation of 12 leading therapies currently available

- An exhaustive examination of major IBD conditions

- Related prevalence and background data

The market for inflammatory bowel disease (IBD) will experience steady and significant growth over the next 5 years. The main driving forces behind IBD market expansion will be the increased uptake of current and novel high-priced biological agents and growth of the diagnosed prevalent populations in the United States and United Kingdom. These novel products will provide more treatment options for patients whose disease is unresponsive to less expensive, conventional IBD therapies (i.e. aminosalicylates, immunosuppressants, and corticosteroids) and for patients who fail infliximab. The availability of additional biologics will expand the percentage of IBD patients treated with these agents as an alternative biological agent is likely to be prescribed if the first one should fail.

Figures for average annual direct costs of treating Crohn's disease per patient in the US have been put at between US$9,000 and US$11,000, whereas European studies have given much lower cost estimates of US$1,100 annually. Much of the total cost of illness relates to extensive interventions required by a small proportion of severely affected individuals. The cost of treating this disease with medications is significant, due in part to the availability of new novel high-value treatments.

Understand the key market sector

The IBD market is taking an increasingly important role in industry's and investors plans. That is why Espicom has published the extensive analysis Inflammatory Bowel Disease Drug Discoveries: What the future holds. The report put the spotlight on current and future drugs that will be used in ulcerative colitis and Crohn's disease, and provides industry and investors with a complete and comprehensive overview of the market for the next 5 years.

A growing and valuable market

Crohn's disease and ulcerative colitis are idiopathic inflammatory disorders affecting the gastrointestinal tract, and are collectively known as inflammatory bowel disease. These 2 disorders are closely related, but separated by distinct clinicopathologic features, including different locations affected within the gastrointestinal tract, diverse histologic patterns of inflammation and various disease-specific complications.

Historically the management of IBD has relied on NSAI drugs such as 5-aminosalicylates (5-ASAs), glucocorticoids, and antibiotics. These therapies are limited by a slow onset of action, incomplete response rate and significant risk of adverse effects. In addition to these compounds immunoregulatory agents used in IBD were expanded to include methotrexate and cyclosporine in select patient populations.

In the past decade, however, renewed hope for patients with IBD has emerged with the development of potent biological therapies that selectively target components of the inflammatory cascade.


Interest in IBD is strong due to its high growth potential. By 2010 it is estimate that total prevalence will increase by 221,000 worldwide, 137,000 with ulcerative colitis and 74,000 with Crohn's disease. This will bring the total number to 2.2 million identified cases worldwide. The growth in the treatable population, allied to high prices for novel and effective treatments, will see the sector grow in importance.


What trends in diagnosis and understanding of IBD conditions are driving the market?

Market leading Remicade (J&J) is forecast to generate US$2.1 billion by 2010 – what contribution to that figures will be made by its indication for Crohns disease?

What potential –and advantages - do Cimzia (UCB) and Humira (CAT/Abbott) have in the valuable TNF inhibitor sector?

Why is Synta Pharma's STA-5326 interleukin inhibitor forecast to generate US$273 million when launched is 2010?

What factors may limit the growth of Shire's/ Ferring's Pentasa?

The answers to these and hundreds of other questions can be found in this report.


Tumour Necrosis factor-alpha inhibitors

Cell adhesion molecule inhibitors

Novel corticosteroids

T-cell modulators

Immune system modulators

Interleukin inhibitors

MAP Kinase inhibitors



- Azulfidine / Salazopyrin (Pfizer)

- Pentasa (Shire/Ferring Pharma)

- Asacol (GSK)

- Colazal/Colazide (Shire/Salix Pharma)


- Entocort EC (AstraZeneca/Prometheus)


- 6-mercaptopurine (6-MP,) Purinethol, Puri-Nethol (GSK/Teva)

- Azathioprine (Imuran, Azasan - GSK)

- Neoral, Sandimmune (Cyclosporin – Novartis)

- Methotrexate (various generic)


Anti-Tumour Necrosis Factors (TNF)

- Remicade (Johnson & Johnson )

- RDP-58 (Genzyme)

- Cimzia (CDP-870 – UCB)

- Humira (Adalimumab – CAT/Abbott)


- Colal-Pred (ATL-2502 - Alizyme)

- Colirest (CBP-1011 - Salix Pharma)

Cell Adhesion Molecule Inhibitors

- Alicaforsen (ISIS Pharma)

- Tysabri (Elan/BiogenIDEC)

- SB683699 (GSK/Tanabe)

- MLN-02 (Millenium Pharma)

Immune System Modulators

- Nuvion (Visilizumab – Protein Design Labs)

- Leukine (Sargramostium - Schering AG)

- HuZaf (Fontilizumab – Protein Design Labs)

- Alequel (Enzo Therapeutics)

Interleukin Inhibitors

- ABT-874 (Abbott)

- STA-5326 (Apilimod mesylate – Synta Pharma)

- CNTO-1275 (Centocor)

- MAP Kinase Inhibitors

- Semapimod (Cytokine)

Table of Contents available upon request

To order this report:

Drug Discovery and Development Industry: Inflammatory Bowel Disease: what the future holds

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

    Nicolas Bombourg
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Johnson & Johnson Wins North American Corporate Ex...
Reportlinker Adds The Outlook for Pharmaceuticals ...